Swiss National Bank lifted its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Rating) by 38.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,981,100 shares of the company's stock after acquiring an additional 554,900 shares during the quarter. Swiss National Bank owned approximately 0.10% of Ginkgo Bioworks worth $3,348,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Itau Unibanco Holding S.A. bought a new position in Ginkgo Bioworks during the 3rd quarter worth approximately $30,000. Avantax Advisory Services Inc. acquired a new position in Ginkgo Bioworks in the third quarter valued at $31,000. Cambridge Investment Research Advisors Inc. acquired a new stake in Ginkgo Bioworks during the 1st quarter worth about $43,000. Claraphi Advisory Network LLC bought a new position in shares of Ginkgo Bioworks in the 3rd quarter worth about $34,000. Finally, Atria Wealth Solutions Inc. bought a new position in shares of Ginkgo Bioworks in the 2nd quarter worth about $30,000. 61.83% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
DNA has been the subject of several recent analyst reports. BTIG Research decreased their target price on Ginkgo Bioworks from $4.00 to $3.00 in a research note on Sunday, March 5th. William Blair downgraded shares of Ginkgo Bioworks from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 11th. Finally, Raymond James reduced their price target on shares of Ginkgo Bioworks from $6.00 to $5.00 and set an "outperform" rating for the company in a report on Friday, March 3rd. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $4.67.
Insiders Place Their Bets
In other news, insider Mark E. Dmytruk sold 29,762 shares of the firm's stock in a transaction that occurred on Wednesday, March 15th. The stock was sold at an average price of $1.31, for a total value of $38,988.22. Following the transaction, the insider now owns 530,736 shares in the company, valued at $695,264.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Mark E. Dmytruk sold 29,762 shares of the stock in a transaction dated Wednesday, March 15th. The shares were sold at an average price of $1.31, for a total value of $38,988.22. Following the completion of the sale, the insider now owns 530,736 shares in the company, valued at $695,264.16. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Reshma P. Shetty sold 37,650 shares of the business's stock in a transaction dated Wednesday, February 22nd. The stock was sold at an average price of $1.65, for a total transaction of $62,122.50. Following the transaction, the insider now owns 13,993,504 shares in the company, valued at $23,089,281.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 512,604 shares of company stock valued at $666,890. Corporate insiders own 17.47% of the company's stock.
Ginkgo Bioworks Trading Down 3.0 %
Shares of DNA opened at $1.28 on Monday. The business's fifty day moving average is $1.27 and its 200 day moving average is $1.63. Ginkgo Bioworks Holdings, Inc. has a 12-month low of $1.12 and a 12-month high of $4.91.
Ginkgo Bioworks (NYSE:DNA - Get Rating) last issued its quarterly earnings data on Wednesday, March 1st. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.26. Ginkgo Bioworks had a negative net margin of 440.87% and a negative return on equity of 97.13%. The firm had revenue of $98.29 million during the quarter, compared to analysts' expectations of $84.41 million. On average, equities research analysts expect that Ginkgo Bioworks Holdings, Inc. will post -0.29 EPS for the current fiscal year.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to email@example.com.
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report